MX2015006192A - Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana. - Google Patents

Info

Publication number

MX2015006192A

MX2015006192A MX2015006192A MX2015006192A MX2015006192A MX 2015006192 A MX2015006192 A MX 2015006192A MX 2015006192 A MX2015006192 A MX 2015006192A MX 2015006192 A MX2015006192 A MX 2015006192A MX 2015006192 A MX2015006192 A MX 2015006192A

Authority

MX

Mexico

Prior art keywords

purin

ethyl

amino

pyrrolidin

methyl

Prior art date

2012-11-16

Links

• Espacenet
• Global Dossier
• Discuss

• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title description 15
• 239000003112 inhibitor Substances 0.000 title description 13
• 108091007960 PI3Ks Proteins 0.000 title description 6
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 319
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
• 238000011282 treatment Methods 0.000 claims abstract description 29
• 208000006673 asthma Diseases 0.000 claims abstract description 21
• 201000010099 disease Diseases 0.000 claims abstract description 16
• 230000001404 mediated effect Effects 0.000 claims abstract description 13
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
• 201000011510 cancer Diseases 0.000 claims abstract description 8
• 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 claims abstract description 7
• 101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 claims abstract description 7
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 3
• 238000002360 preparation method Methods 0.000 claims description 203
• -1 chloro, methyl Chemical group 0.000 claims description 160
• OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 131
• 125000000217 alkyl group Chemical group 0.000 claims description 89
• 150000003839 salts Chemical class 0.000 claims description 61
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 42
• 125000001424 substituent group Chemical group 0.000 claims description 32
• 239000003814 drug Substances 0.000 claims description 27
• 125000003118 aryl group Chemical group 0.000 claims description 21
• 125000001072 heteroaryl group Chemical group 0.000 claims description 16
• 229910052799 carbon Inorganic materials 0.000 claims description 15
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
• 239000008194 pharmaceutical composition Substances 0.000 claims description 15
• 241000124008 Mammalia Species 0.000 claims description 13
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
• 206010003246 arthritis Diseases 0.000 claims description 11
• 229910052739 hydrogen Inorganic materials 0.000 claims description 11
• 230000005764 inhibitory process Effects 0.000 claims description 11
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
• 239000001257 hydrogen Substances 0.000 claims description 10
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
• 239000000843 powder Substances 0.000 claims description 8
• 229940124597 therapeutic agent Drugs 0.000 claims description 7
• WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 6
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
• 229910052757 nitrogen Inorganic materials 0.000 claims description 5
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 4
• 125000003545 alkoxy group Chemical group 0.000 claims description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
• 229910052717 sulfur Inorganic materials 0.000 claims description 4
• 208000023275 Autoimmune disease Diseases 0.000 claims description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
• 125000000304 alkynyl group Chemical group 0.000 claims description 2
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
• 229910052760 oxygen Inorganic materials 0.000 claims description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 75
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 71
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 53
• 229960000643 adenine Drugs 0.000 claims 30
• 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims 24
• 125000004404 heteroalkyl group Chemical group 0.000 claims 11
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 8
• NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims 8
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
• 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 7
• 125000000753 cycloalkyl group Chemical group 0.000 claims 7
• 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 claims 6
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 5
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 4
• 208000003456 Juvenile Arthritis Diseases 0.000 claims 4
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 4
• 229910052736 halogen Inorganic materials 0.000 claims 4
• 150000002367 halogens Chemical class 0.000 claims 4
• 210000002345 respiratory system Anatomy 0.000 claims 4
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 3
• 125000001188 haloalkyl group Chemical group 0.000 claims 3
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
• 206010014561 Emphysema Diseases 0.000 claims 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
• 208000011623 Obstructive Lung disease Diseases 0.000 claims 2
• 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 claims 2
• 230000036428 airway hyperreactivity Effects 0.000 claims 2
• 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
• 201000009961 allergic asthma Diseases 0.000 claims 2
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
• 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
• 206010006451 bronchitis Diseases 0.000 claims 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
• 208000023819 chronic asthma Diseases 0.000 claims 2
• 125000004093 cyano group Chemical group *C#N 0.000 claims 2
• 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 2
• 230000003111 delayed effect Effects 0.000 claims 2
• 208000024711 extrinsic asthma Diseases 0.000 claims 2
• 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 2
• 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 2
• 201000010659 intrinsic asthma Diseases 0.000 claims 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
• 230000000414 obstructive effect Effects 0.000 claims 2
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 2
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
• 230000000306 recurrent effect Effects 0.000 claims 2
• 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 2
• KYQNNKQWMYRULI-UHFFFAOYSA-N (2,5-dimethyl-1,3-oxazol-4-yl)-[3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)C=1N=C(C)OC=1C KYQNNKQWMYRULI-UHFFFAOYSA-N 0.000 claims 1
• UXMIWVISLJQNJQ-UHFFFAOYSA-N 1-[3-[(9-ethyl-8-methylpurin-6-yl)amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCC1NC1=NC=NC2=C1N=C(C)N2CC UXMIWVISLJQNJQ-UHFFFAOYSA-N 0.000 claims 1
• IFQPBOOTNHRBQE-UHFFFAOYSA-N 1-[3-[[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]amino]piperidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCCC1NC1=NC=NC2=C1N=C(C1=C(N(CC)N=C1)C)N2C IFQPBOOTNHRBQE-UHFFFAOYSA-N 0.000 claims 1
• XZTVMQMWAPLTFI-UHFFFAOYSA-N 1-[3-[[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCC1NC1=NC=NC2=C1N=C(C1=C(N(CC)N=C1)C)N2C XZTVMQMWAPLTFI-UHFFFAOYSA-N 0.000 claims 1
• RDMLKTNAOHEDTQ-UHFFFAOYSA-N 1-[3-[[8-(1h-indazol-5-yl)-9-methylpurin-6-yl]amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCC1NC1=NC=NC2=C1N=C(C=1C=C3C=NNC3=CC=1)N2C RDMLKTNAOHEDTQ-UHFFFAOYSA-N 0.000 claims 1
• WNQPNFQACFFKON-UHFFFAOYSA-N 1-[3-[[8-(1h-indazol-6-yl)-9-methylpurin-6-yl]amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCC1NC1=NC=NC2=C1N=C(C=1C=C3NN=CC3=CC=1)N2C WNQPNFQACFFKON-UHFFFAOYSA-N 0.000 claims 1
• OKHFDRAIGDVMND-UHFFFAOYSA-N 1-[3-[[8-(1h-indol-6-yl)-9-methylpurin-6-yl]amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCC1NC1=NC=NC2=C1N=C(C=1C=C3NC=CC3=CC=1)N2C OKHFDRAIGDVMND-UHFFFAOYSA-N 0.000 claims 1
• MOHJKIVOFAEZSE-UHFFFAOYSA-N 1-[3-[[8-(difluoromethyl)-9-ethylpurin-6-yl]amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCC1NC1=NC=NC2=C1N=C(C(F)F)N2CC MOHJKIVOFAEZSE-UHFFFAOYSA-N 0.000 claims 1
• QALKCKKNCJAETK-UHFFFAOYSA-N 1-[3-[[9-ethyl-8-(2-methylpropyl)purin-6-yl]amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCC1NC1=NC=NC2=C1N=C(CC(C)C)N2CC QALKCKKNCJAETK-UHFFFAOYSA-N 0.000 claims 1
• IDVDFMOYBQFSBB-UHFFFAOYSA-N 1-[3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]piperidin-1-yl]-2-methylpropan-1-one Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC1CCCN(C(=O)C(C)C)C1 IDVDFMOYBQFSBB-UHFFFAOYSA-N 0.000 claims 1
• NHQHLZBRLZVTTL-UHFFFAOYSA-N 1-[3-[[9-ethyl-8-(trifluoromethyl)purin-6-yl]amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCC1NC1=NC=NC2=C1N=C(C(F)(F)F)N2CC NHQHLZBRLZVTTL-UHFFFAOYSA-N 0.000 claims 1
• OXPQVRKTSGHGTB-UHFFFAOYSA-N 1-[3-[[9-methyl-8-(2-methylpropyl)purin-6-yl]amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCC1NC1=NC=NC2=C1N=C(CC(C)C)N2C OXPQVRKTSGHGTB-UHFFFAOYSA-N 0.000 claims 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
• BBDYCTZQLPNUIB-UHFFFAOYSA-N 2-(fluoromethyl)cyclopropane-1-carbaldehyde Chemical compound FCC1C(C1)C=O BBDYCTZQLPNUIB-UHFFFAOYSA-N 0.000 claims 1
• ZXLBCMPKXNONCZ-UHFFFAOYSA-N 2-amino-1-[3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]-2-methylpropan-1-one Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC1CCN(C(=O)C(C)(C)N)C1 ZXLBCMPKXNONCZ-UHFFFAOYSA-N 0.000 claims 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
• SDPIXJJMLQIKSR-UHFFFAOYSA-N 3-[[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]amino]-1-(2-methylpropyl)pyrrolidin-2-one Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)NC1C(N(CC1)CC(C)C)=O)C SDPIXJJMLQIKSR-UHFFFAOYSA-N 0.000 claims 1
• GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims 1
• 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 1
• PSAUDVOTVCGJOH-UHFFFAOYSA-N 6-[[1-(cyclobutanecarbonyl)pyrrolidin-3-yl]amino]-9-ethyl-n-(2,2,2-trifluoroethyl)purine-8-carboxamide Chemical compound N1=CN=C2N(CC)C(C(=O)NCC(F)(F)F)=NC2=C1NC(C1)CCN1C(=O)C1CCC1 PSAUDVOTVCGJOH-UHFFFAOYSA-N 0.000 claims 1
• VYVOCSWFODLOPE-UHFFFAOYSA-N 6-[[1-(cyclopropanecarbonyl)pyrrolidin-3-yl]amino]-9-ethyl-n,n-dimethylpurine-8-carboxamide Chemical compound N1=CN=C2N(CC)C(C(=O)N(C)C)=NC2=C1NC(C1)CCN1C(=O)C1CC1 VYVOCSWFODLOPE-UHFFFAOYSA-N 0.000 claims 1
• PXQJLZGWLFDFHP-UHFFFAOYSA-N 6-[[1-(cyclopropanecarbonyl)pyrrolidin-3-yl]amino]-9-ethyl-n-(2-methoxyethyl)purine-8-carboxamide Chemical compound N1=CN=C2N(CC)C(C(=O)NCCOC)=NC2=C1NC(C1)CCN1C(=O)C1CC1 PXQJLZGWLFDFHP-UHFFFAOYSA-N 0.000 claims 1
• SBIKYKNVXSNVEZ-UHFFFAOYSA-N 6-[[1-(cyclopropanecarbonyl)pyrrolidin-3-yl]amino]-9-ethyl-n-(oxetan-3-yl)purine-8-carboxamide Chemical compound N1=CN=C2N(CC)C(C(=O)NC3COC3)=NC2=C1NC(C1)CCN1C(=O)C1CC1 SBIKYKNVXSNVEZ-UHFFFAOYSA-N 0.000 claims 1
• PRUGVLLZYGAAQX-UHFFFAOYSA-N 6-[[1-(cyclopropanecarbonyl)pyrrolidin-3-yl]amino]-9-ethyl-n-phenylpurine-8-carboxamide Chemical compound N1=CN=C2N(CC)C(C(=O)NC=3C=CC=CC=3)=NC2=C1NC(C1)CCN1C(=O)C1CC1 PRUGVLLZYGAAQX-UHFFFAOYSA-N 0.000 claims 1
• DNRLNZVPSBUEBO-UHFFFAOYSA-N 6-[[1-(cyclopropanecarbonyl)pyrrolidin-3-yl]amino]-n-(cyclopropylmethyl)-9-ethylpurine-8-carboxamide Chemical compound N1=CN=C2N(CC)C(C(=O)NCC3CC3)=NC2=C1NC(C1)CCN1C(=O)C1CC1 DNRLNZVPSBUEBO-UHFFFAOYSA-N 0.000 claims 1
• REJPIVHCBUMHBJ-UHFFFAOYSA-N 9-ethyl-8-(2-methylpyrimidin-5-yl)-n-(1-pyridin-2-ylpyrrolidin-3-yl)purin-6-amine Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C1=CC=CC=N1 REJPIVHCBUMHBJ-UHFFFAOYSA-N 0.000 claims 1
• SSXXHNAIFJNTNF-UHFFFAOYSA-N 9-ethyl-8-(2-methylpyrimidin-5-yl)-n-(1-pyrimidin-2-ylpyrrolidin-3-yl)purin-6-amine Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C1=NC=CC=N1 SSXXHNAIFJNTNF-UHFFFAOYSA-N 0.000 claims 1
• QNBVTCGTDHHLCT-UHFFFAOYSA-N 9-ethyl-N-(1-isoquinolin-1-ylpyrrolidin-3-yl)-8-(2-methylpyrimidin-5-yl)purin-6-amine Chemical compound C(C)N1C2=NC=NC(=C2N=C1C=1C=NC(=NC1)C)NC1CN(CC1)C1=NC=CC2=CC=CC=C12 QNBVTCGTDHHLCT-UHFFFAOYSA-N 0.000 claims 1
• SBHGRGKVWJSLGS-UHFFFAOYSA-N 9-ethyl-n-[1-(6-methoxypyridin-2-yl)pyrrolidin-3-yl]-8-(2-methylpyrimidin-5-yl)purin-6-amine Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C1=CC=CC(OC)=N1 SBHGRGKVWJSLGS-UHFFFAOYSA-N 0.000 claims 1
• 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
• DDDIIIUDDGNOPK-UHFFFAOYSA-N CC1=C(N=NS1)C(=O)N1CC(CC1)C1=NC(=C2N=CNC2=N1)N Chemical compound CC1=C(N=NS1)C(=O)N1CC(CC1)C1=NC(=C2N=CNC2=N1)N DDDIIIUDDGNOPK-UHFFFAOYSA-N 0.000 claims 1
• WHWFYGQVOSQYQA-UHFFFAOYSA-N CCn1c(nc2c(NC3CCN(C3)C(=O)N3CC(C3)OC)ncnc12)C(=O)NCC(F)(F)F Chemical compound CCn1c(nc2c(NC3CCN(C3)C(=O)N3CC(C3)OC)ncnc12)C(=O)NCC(F)(F)F WHWFYGQVOSQYQA-UHFFFAOYSA-N 0.000 claims 1
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
• FJMNVSUWJVEXHR-UHFFFAOYSA-N [3-[(8-tert-butyl-9-ethylpurin-6-yl)amino]pyrrolidin-1-yl]-cyclopropylmethanone Chemical compound N1=CN=C2N(CC)C(C(C)(C)C)=NC2=C1NC(C1)CCN1C(=O)C1CC1 FJMNVSUWJVEXHR-UHFFFAOYSA-N 0.000 claims 1
• CDHAOCUUOAMMOI-UHFFFAOYSA-N [3-[[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]amino]azetidin-1-yl]-(oxan-4-yl)methanone Chemical compound CCN1N=CC(C=2N(C3=NC=NC(NC4CN(C4)C(=O)C4CCOCC4)=C3N=2)C)=C1C CDHAOCUUOAMMOI-UHFFFAOYSA-N 0.000 claims 1
• WFVKABQFHLSPFH-UHFFFAOYSA-N [3-[[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]amino]pyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound CCN1N=CC(C=2N(C3=NC=NC(NC4CN(CC4)C(=O)C4CCOCC4)=C3N=2)C)=C1C WFVKABQFHLSPFH-UHFFFAOYSA-N 0.000 claims 1
• OLJCGTWFJRUJHM-UHFFFAOYSA-N [3-[[8-(5-chloropyridin-3-yl)-9-ethylpurin-6-yl]amino]pyrrolidin-1-yl]-cyclopropylmethanone Chemical compound N1=CN=C2N(CC)C(C=3C=C(Cl)C=NC=3)=NC2=C1NC(C1)CCN1C(=O)C1CC1 OLJCGTWFJRUJHM-UHFFFAOYSA-N 0.000 claims 1
• WJTTZZDOGXZXRA-UHFFFAOYSA-N [3-[[8-(benzimidazol-1-yl)-9-ethylpurin-6-yl]amino]pyrrolidin-1-yl]-cyclopropylmethanone Chemical compound N1=CN=C2N(CC)C(N3C4=CC=CC=C4N=C3)=NC2=C1NC(C1)CCN1C(=O)C1CC1 WJTTZZDOGXZXRA-UHFFFAOYSA-N 0.000 claims 1
• OEADPOGZBWJIRS-UHFFFAOYSA-N [3-[[8-(difluoromethyl)-9-ethylpurin-6-yl]amino]pyrrolidin-1-yl]-(1,3-oxazol-4-yl)methanone Chemical compound CCn1c(nc2c(NC3CCN(C3)C(=O)c3cocn3)ncnc12)C(F)F OEADPOGZBWJIRS-UHFFFAOYSA-N 0.000 claims 1
• NDOXWSIBBHIJOY-PIJUOVFKSA-N [3-[[8-(difluoromethyl)-9-ethylpurin-6-yl]amino]pyrrolidin-1-yl]-[(2r)-1-methylpyrrolidin-2-yl]methanone Chemical compound N1=CN=C2N(CC)C(C(F)F)=NC2=C1NC(C1)CCN1C(=O)[C@H]1CCCN1C NDOXWSIBBHIJOY-PIJUOVFKSA-N 0.000 claims 1
• PIGUHLRPVFFTQD-UHFFFAOYSA-N [3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]-(1,3-oxazol-4-yl)methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)C1=COC=N1 PIGUHLRPVFFTQD-UHFFFAOYSA-N 0.000 claims 1
• FITSFBHFRMWHOA-UHFFFAOYSA-N [3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]-(1,3-oxazol-5-yl)methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)C1=CN=CO1 FITSFBHFRMWHOA-UHFFFAOYSA-N 0.000 claims 1
• REKZULRBVKCCEI-UHFFFAOYSA-N [3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)C1CCOCC1 REKZULRBVKCCEI-UHFFFAOYSA-N 0.000 claims 1
• QERDVYRIDNEVHN-ZYMOGRSISA-N [3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]-[(2r)-1-methylpyrrolidin-2-yl]methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)[C@H]1CCCN1C QERDVYRIDNEVHN-ZYMOGRSISA-N 0.000 claims 1
• MTXBPKFICSRQEH-UHFFFAOYSA-N [3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]-morpholin-4-ylmethanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)N1CCOCC1 MTXBPKFICSRQEH-UHFFFAOYSA-N 0.000 claims 1
• STDPDMIGZDZTIK-UHFFFAOYSA-N [3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]-piperidin-1-ylmethanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)N1CCCCC1 STDPDMIGZDZTIK-UHFFFAOYSA-N 0.000 claims 1
• LDSXXLPWEJSVMG-UHFFFAOYSA-N [3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]-piperidin-2-ylmethanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)C1CCCCN1 LDSXXLPWEJSVMG-UHFFFAOYSA-N 0.000 claims 1
• 125000003282 alkyl amino group Chemical group 0.000 claims 1
• 125000004419 alkynylene group Chemical group 0.000 claims 1
• 125000005015 aryl alkynyl group Chemical group 0.000 claims 1
• VHCDUVIIGCOHEP-UHFFFAOYSA-N azetidin-1-yl-[3-[[8-(difluoromethyl)-9-ethylpurin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C(F)F)=NC2=C1NC(C1)CCN1C(=O)N1CCC1 VHCDUVIIGCOHEP-UHFFFAOYSA-N 0.000 claims 1
• IIBXETVFOUKENY-UHFFFAOYSA-N azetidin-1-yl-[3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]cyclopentyl]methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCC1C(=O)N1CCC1 IIBXETVFOUKENY-UHFFFAOYSA-N 0.000 claims 1
• WCIZRKILCUBCMO-UHFFFAOYSA-N azetidin-1-yl-[3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)N1CCC1 WCIZRKILCUBCMO-UHFFFAOYSA-N 0.000 claims 1
• 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 1
• KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 claims 1
• MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 claims 1
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
• HNMLTQPLXDSEOU-UHFFFAOYSA-N cyclobutyl-[3-[[8-(difluoromethyl)-9-ethylpurin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C(F)F)=NC2=C1NC(C1)CCN1C(=O)C1CCC1 HNMLTQPLXDSEOU-UHFFFAOYSA-N 0.000 claims 1
• JLHUINFRYGKMQX-UHFFFAOYSA-N cyclobutyl-[3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)C1CCC1 JLHUINFRYGKMQX-UHFFFAOYSA-N 0.000 claims 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
• XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 claims 1
• MDIJIUPZFYYLAF-UHFFFAOYSA-N cyclopentyl-[3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)C1CCCC1 MDIJIUPZFYYLAF-UHFFFAOYSA-N 0.000 claims 1
• SSTXXZHWZORTDS-UHFFFAOYSA-N cyclopropyl-[3-[(9-ethyl-8-propan-2-ylpurin-6-yl)amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C(C)C)=NC2=C1NC(C1)CCN1C(=O)C1CC1 SSTXXZHWZORTDS-UHFFFAOYSA-N 0.000 claims 1
• RJPMXGFVNRUQFM-UHFFFAOYSA-N cyclopropyl-[3-[[8-(difluoromethyl)-9-ethylpurin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C(F)F)=NC2=C1NC(C1)CCN1C(=O)C1CC1 RJPMXGFVNRUQFM-UHFFFAOYSA-N 0.000 claims 1
• YBYVIDZVAIZIRF-UHFFFAOYSA-N cyclopropyl-[3-[[9-ethyl-8-(2-methoxyethyl)purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(CCOC)=NC2=C1NC(C1)CCN1C(=O)C1CC1 YBYVIDZVAIZIRF-UHFFFAOYSA-N 0.000 claims 1
• DADGJAZOHPBTCZ-UHFFFAOYSA-N cyclopropyl-[3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C1)CCN1C(=O)C1CC1 DADGJAZOHPBTCZ-UHFFFAOYSA-N 0.000 claims 1
• GJXJCIYNXXLHHC-UHFFFAOYSA-N cyclopropyl-[3-[[9-ethyl-8-(5-phenylpyridin-3-yl)purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C=3C=C(C=NC=3)C=3C=CC=CC=3)=NC2=C1NC(C1)CCN1C(=O)C1CC1 GJXJCIYNXXLHHC-UHFFFAOYSA-N 0.000 claims 1
• AIGZIXZEZSQVDF-UHFFFAOYSA-N cyclopropyl-[3-[[9-ethyl-8-(6-methoxypyridin-3-yl)purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(OC)=CC=3)=NC2=C1NC(C1)CCN1C(=O)C1CC1 AIGZIXZEZSQVDF-UHFFFAOYSA-N 0.000 claims 1
• XLFKFCUZSQBYJM-UHFFFAOYSA-N cyclopropyl-[3-[[9-ethyl-8-(methoxymethyl)purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(COC)=NC2=C1NC(C1)CCN1C(=O)C1CC1 XLFKFCUZSQBYJM-UHFFFAOYSA-N 0.000 claims 1
• KSKZJGFTYPHBCA-UHFFFAOYSA-N cyclopropyl-[3-[[9-ethyl-8-(pyrrolidine-1-carbonyl)purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C(=O)N3CCCC3)=NC2=C1NC(C1)CCN1C(=O)C1CC1 KSKZJGFTYPHBCA-UHFFFAOYSA-N 0.000 claims 1
• OKOVWNCGTRYCMQ-UHFFFAOYSA-N cyclopropyl-[3-[[9-ethyl-8-[4-(trifluoromethyl)imidazol-1-yl]purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(N3C=C(N=C3)C(F)(F)F)=NC2=C1NC(C1)CCN1C(=O)C1CC1 OKOVWNCGTRYCMQ-UHFFFAOYSA-N 0.000 claims 1
• UQSZXODZGWENSO-UHFFFAOYSA-N cyclopropyl-[3-[[9-ethyl-8-[6-(trifluoromethyl)pyridin-3-yl]purin-6-yl]amino]pyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(=CC=3)C(F)(F)F)=NC2=C1NC(C1)CCN1C(=O)C1CC1 UQSZXODZGWENSO-UHFFFAOYSA-N 0.000 claims 1
• RIYFJGMLTLZGPW-UHFFFAOYSA-N cyclopropyl-[4-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]-3,3-difluoropyrrolidin-1-yl]methanone Chemical compound N1=CN=C2N(CC)C(C=3C=NC(C)=NC=3)=NC2=C1NC(C(C1)(F)F)CN1C(=O)C1CC1 RIYFJGMLTLZGPW-UHFFFAOYSA-N 0.000 claims 1
• NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 claims 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims 1
• 125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
• 125000001153 fluoro group Chemical group F* 0.000 claims 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
• JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 claims 1
• LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 claims 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
• RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
• 229940124780 PI3K delta inhibitor Drugs 0.000 abstract 1
• 239000000203 mixture Substances 0.000 description 273
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 203
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 180
• 239000000243 solution Substances 0.000 description 139
• 239000000543 intermediate Substances 0.000 description 103
• 238000006243 chemical reaction Methods 0.000 description 91
• 239000011541 reaction mixture Substances 0.000 description 88
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 87
• 235000019439 ethyl acetate Nutrition 0.000 description 68
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 65
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 64
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
• 239000002253 acid Substances 0.000 description 52
• 239000002904 solvent Substances 0.000 description 47
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 45
• 239000000706 filtrate Substances 0.000 description 45
• 238000005481 NMR spectroscopy Methods 0.000 description 43
• 239000012044 organic layer Substances 0.000 description 39
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 34
• 238000000034 method Methods 0.000 description 32
• 230000014759 maintenance of location Effects 0.000 description 27
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
• 239000003607 modifier Substances 0.000 description 26
• 238000002953 preparative HPLC Methods 0.000 description 26
• 230000002441 reversible effect Effects 0.000 description 26
• 229920006395 saturated elastomer Polymers 0.000 description 26
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 26
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 25
• 238000003756 stirring Methods 0.000 description 25
• 229940126062 Compound A Drugs 0.000 description 24
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 24
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
• 238000001514 detection method Methods 0.000 description 24
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
• 238000004007 reversed phase HPLC Methods 0.000 description 21
• 150000001412 amines Chemical class 0.000 description 20
• 239000003795 chemical substances by application Substances 0.000 description 20
• 239000002245 particle Substances 0.000 description 20
• 230000015572 biosynthetic process Effects 0.000 description 19
• 238000004440 column chromatography Methods 0.000 description 18
• 239000000047 product Substances 0.000 description 18
• 230000002829 reductive effect Effects 0.000 description 18
• 238000010898 silica gel chromatography Methods 0.000 description 18
• 125000004429 atom Chemical group 0.000 description 17
• 238000003786 synthesis reaction Methods 0.000 description 17
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 16
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
• 230000000694 effects Effects 0.000 description 15
• 150000002148 esters Chemical class 0.000 description 15
• 239000003921 oil Substances 0.000 description 15
• 235000019198 oils Nutrition 0.000 description 15
• 239000000741 silica gel Substances 0.000 description 15
• 229910002027 silica gel Inorganic materials 0.000 description 15
• 229940079593 drug Drugs 0.000 description 14
• 239000003208 petroleum Substances 0.000 description 14
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 13
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 13
• 238000000746 purification Methods 0.000 description 13
• 229940086542 triethylamine Drugs 0.000 description 13
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
• 150000007942 carboxylates Chemical class 0.000 description 12
• 238000009472 formulation Methods 0.000 description 12
• 239000010410 layer Substances 0.000 description 12
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
• 239000007787 solid Substances 0.000 description 12
• 238000003556 assay Methods 0.000 description 11
• 239000012298 atmosphere Substances 0.000 description 11
• 239000012267 brine Substances 0.000 description 11
• 125000004432 carbon atom Chemical group C* 0.000 description 11
• 210000004027 cell Anatomy 0.000 description 11
• 238000004587 chromatography analysis Methods 0.000 description 11
• 239000012453 solvate Substances 0.000 description 11
• 239000000725 suspension Substances 0.000 description 11
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
• 239000007821 HATU Substances 0.000 description 10
• 125000004122 cyclic group Chemical group 0.000 description 10
• 125000000623 heterocyclic group Chemical group 0.000 description 10
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 10
• 238000005160 1H NMR spectroscopy Methods 0.000 description 9
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 239000004480 active ingredient Substances 0.000 description 9
• 125000002619 bicyclic group Chemical group 0.000 description 9
• 239000000284 extract Substances 0.000 description 9
• 239000000499 gel Substances 0.000 description 9
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
• 239000000546 pharmaceutical excipient Substances 0.000 description 9
• 229910052938 sodium sulfate Inorganic materials 0.000 description 9
• 235000011152 sodium sulphate Nutrition 0.000 description 9
• 201000009030 Carcinoma Diseases 0.000 description 8
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
• 238000005859 coupling reaction Methods 0.000 description 8
• 239000000651 prodrug Substances 0.000 description 8
• 229940002612 prodrug Drugs 0.000 description 8
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
• 208000011580 syndromic disease Diseases 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 150000007513 acids Chemical class 0.000 description 7
• 239000013543 active substance Substances 0.000 description 7
• 235000019270 ammonium chloride Nutrition 0.000 description 7
• 239000002131 composite material Substances 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 229910000027 potassium carbonate Inorganic materials 0.000 description 7
• 238000012746 preparative thin layer chromatography Methods 0.000 description 7
• 235000017557 sodium bicarbonate Nutrition 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 125000001931 aliphatic group Chemical group 0.000 description 6
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
• 230000008878 coupling Effects 0.000 description 6
• 238000010168 coupling process Methods 0.000 description 6
• ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 6
• 125000005842 heteroatom Chemical group 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
• 102000038030 PI3Ks Human genes 0.000 description 5
• 206010039491 Sarcoma Diseases 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 239000007900 aqueous suspension Substances 0.000 description 5
• 150000001721 carbon Chemical group 0.000 description 5
• 239000007859 condensation product Substances 0.000 description 5
• 238000005227 gel permeation chromatography Methods 0.000 description 5
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 239000011259 mixed solution Substances 0.000 description 5
• 230000003287 optical effect Effects 0.000 description 5
• 239000003380 propellant Substances 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 208000003200 Adenoma Diseases 0.000 description 4
• 206010001233 Adenoma benign Diseases 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
• LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• 150000001299 aldehydes Chemical class 0.000 description 4
• 150000008064 anhydrides Chemical class 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• 238000004296 chiral HPLC Methods 0.000 description 4
• 239000012043 crude product Substances 0.000 description 4
• 235000014113 dietary fatty acids Nutrition 0.000 description 4
• 230000006806 disease prevention Effects 0.000 description 4
• 239000002270 dispersing agent Substances 0.000 description 4
• VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 4
• 239000000194 fatty acid Substances 0.000 description 4
• 229930195729 fatty acid Natural products 0.000 description 4
• 150000004665 fatty acids Chemical class 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 125000000524 functional group Chemical group 0.000 description 4
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 125000002950 monocyclic group Chemical group 0.000 description 4
• 231100000252 nontoxic Toxicity 0.000 description 4
• 230000003000 nontoxic effect Effects 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 150000003254 radicals Chemical class 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 3
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
• YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
• 101100297694 Arabidopsis thaliana PIP2-7 gene Proteins 0.000 description 3
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 101150037263 PIP2 gene Proteins 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 101100456541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MEC3 gene Proteins 0.000 description 3
• 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 3
• 101100483663 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UFD1 gene Proteins 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 238000010256 biochemical assay Methods 0.000 description 3
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
• 229910000024 caesium carbonate Inorganic materials 0.000 description 3
• 125000002837 carbocyclic group Chemical group 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 238000010828 elution Methods 0.000 description 3
• 238000005755 formation reaction Methods 0.000 description 3
• 208000027866 inflammatory disease Diseases 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 230000000155 isotopic effect Effects 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 238000010992 reflux Methods 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 239000000377 silicon dioxide Substances 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 229910021653 sulphate ion Inorganic materials 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 240000002234 Allium sativum Species 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
• 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
• 239000007832 Na2SO4 Substances 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
• 241000720974 Protium Species 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
• 238000006069 Suzuki reaction reaction Methods 0.000 description 2
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
• PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000011149 active material Substances 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 125000003342 alkenyl group Chemical group 0.000 description 2
• 231100000360 alopecia Toxicity 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
• 239000001099 ammonium carbonate Substances 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 229910052786 argon Inorganic materials 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
• XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
• KBQXDPRNSDVNLB-UHFFFAOYSA-L calcium;carbonic acid;hydrogen phosphate Chemical compound [Ca+2].OC(O)=O.OP([O-])([O-])=O KBQXDPRNSDVNLB-UHFFFAOYSA-L 0.000 description 2
• 150000003857 carboxamides Chemical class 0.000 description 2
• 239000012876 carrier material Substances 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 238000010568 chiral column chromatography Methods 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
• WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• 150000004985 diamines Chemical class 0.000 description 2
• KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 2
• 238000006073 displacement reaction Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 150000002081 enamines Chemical group 0.000 description 2
• 239000012065 filter cake Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 235000004611 garlic Nutrition 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 239000003906 humectant Substances 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 230000003463 hyperproliferative effect Effects 0.000 description 2
• 229910052738 indium Inorganic materials 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
• WOSISLOTWLGNKT-UHFFFAOYSA-L iron(2+);dichloride;hexahydrate Chemical compound O.O.O.O.O.O.Cl[Fe]Cl WOSISLOTWLGNKT-UHFFFAOYSA-L 0.000 description 2
• 150000002576 ketones Chemical class 0.000 description 2
• DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical compound COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 description 2
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
• 208000003747 lymphoid leukemia Diseases 0.000 description 2
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
• 235000019341 magnesium sulphate Nutrition 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 239000012038 nucleophile Substances 0.000 description 2
• 150000002923 oximes Chemical class 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
• 206010039083 rhinitis Diseases 0.000 description 2
• 125000006413 ring segment Chemical group 0.000 description 2
• 239000012312 sodium hydride Substances 0.000 description 2
• 229910000104 sodium hydride Inorganic materials 0.000 description 2
• 238000004611 spectroscopical analysis Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 239000003039 volatile agent Substances 0.000 description 2
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
• YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 description 1
• IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
• TUHIBIVYQLRGME-UHFFFAOYSA-N 2-cyclopropylacetaldehyde Chemical compound O=CCC1CC1 TUHIBIVYQLRGME-UHFFFAOYSA-N 0.000 description 1
• SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
• GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
• BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
• JHRPHASLIZOEBJ-UHFFFAOYSA-N 2-methylpyridine-3-carbaldehyde Chemical compound CC1=NC=CC=C1C=O JHRPHASLIZOEBJ-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• IBOFVQJTBBUKMU-UHFFFAOYSA-N 4,4'-methylene-bis-(2-chloroaniline) Chemical compound C1=C(Cl)C(N)=CC=C1CC1=CC=C(N)C(Cl)=C1 IBOFVQJTBBUKMU-UHFFFAOYSA-N 0.000 description 1
• VGKZBAMIYUHSMU-UHFFFAOYSA-N 4-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylic acid Chemical compound OC(=O)C1CCC(NC(=O)N(CCCl)N=O)CC1 VGKZBAMIYUHSMU-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 241000132092 Aster Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 206010004659 Biliary cirrhosis Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
• QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010008263 Cervical dysplasia Diseases 0.000 description 1
• 201000005262 Chondroma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
• NUGKZPIIWZOBBN-UHFFFAOYSA-N Cl.O=C=O Chemical compound Cl.O=C=O NUGKZPIIWZOBBN-UHFFFAOYSA-N 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
• 241000065675 Cyclops Species 0.000 description 1
• 102000010918 Cysteinyl leukotriene receptors Human genes 0.000 description 1
• 108050001116 Cysteinyl leukotriene receptors Proteins 0.000 description 1
• 102100034032 Cytohesin-3 Human genes 0.000 description 1
• 101710160297 Cytohesin-3 Proteins 0.000 description 1
• 241001455191 Dasyurus albopunctatus Species 0.000 description 1
• BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
• 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000007569 Giant Cell Tumors Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
• 208000002927 Hamartoma Diseases 0.000 description 1
• 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
• 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010021067 Hypopituitarism Diseases 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 241000347881 Kadua laxiflora Species 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 206010024612 Lipoma Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
• 241001123862 Mico Species 0.000 description 1
• UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• XGEAUXVPBXUBKN-WUFINQPMSA-N Obamegine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=C(OC3=C(OC)C=C4CCN(C)[C@H](C4=C3)CC3=CC=C(C=C3)O3)C=21)O)OC)C1=CC=C(O)C3=C1 XGEAUXVPBXUBKN-WUFINQPMSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 206010031149 Osteitis Diseases 0.000 description 1
• 208000000035 Osteochondroma Diseases 0.000 description 1
• 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 239000005662 Paraffin oil Substances 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
• 102100030264 Pleckstrin Human genes 0.000 description 1
• 208000020424 Polyglandular disease Diseases 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 208000006311 Pyoderma Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 102000013275 Somatomedins Human genes 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• CQZITAWPXREEND-UHFFFAOYSA-N [C].Cl Chemical compound [C].Cl CQZITAWPXREEND-UHFFFAOYSA-N 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• QVZJIDDGYMVUJG-UHFFFAOYSA-N acetonitrile;carbonic acid Chemical compound CC#N.OC(O)=O QVZJIDDGYMVUJG-UHFFFAOYSA-N 0.000 description 1
• PWUBONDMIMDOQY-UHFFFAOYSA-N acetonitrile;hydrochloride Chemical compound Cl.CC#N PWUBONDMIMDOQY-UHFFFAOYSA-N 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000010398 acute inflammatory response Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 208000028004 allergic respiratory disease Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 238000010640 amide synthesis reaction Methods 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000001078 anti-cholinergic effect Effects 0.000 description 1
• 230000000843 anti-fungal effect Effects 0.000 description 1
• 230000001387 anti-histamine Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
• 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
• 229960005207 auranofin Drugs 0.000 description 1
• 229960004574 azelastine Drugs 0.000 description 1
• HGQULGDOROIPJN-UHFFFAOYSA-N azetidin-1-ium;chloride Chemical compound Cl.C1CNC1 HGQULGDOROIPJN-UHFFFAOYSA-N 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 150000005347 biaryls Chemical group 0.000 description 1
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 1
• 229960000585 bitolterol mesylate Drugs 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 208000018339 bone inflammation disease Diseases 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 201000008273 brain germinoma Diseases 0.000 description 1
• CKOVQQULGNBJAP-UHFFFAOYSA-N bromane Chemical compound Br.Br.Br CKOVQQULGNBJAP-UHFFFAOYSA-N 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
• 229910052792 caesium Inorganic materials 0.000 description 1
• TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910021386 carbon form Inorganic materials 0.000 description 1
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 238000009104 chemotherapy regimen Methods 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 229960003728 ciclesonide Drugs 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229910052681 coesite Inorganic materials 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 229910052906 cristobalite Inorganic materials 0.000 description 1
• 239000010779 crude oil Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
• 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
• TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 1
• IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 229940112141 dry powder inhaler Drugs 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 125000002587 enol group Chemical group 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
• 125000005677 ethinylene group Chemical class [*:2]C#C[*:1] 0.000 description 1
• RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
• WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
• 229960004884 fluconazole Drugs 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 230000026030 halogenation Effects 0.000 description 1
• 238000005658 halogenation reaction Methods 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 125000001976 hemiacetal group Chemical group 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 1
• VOAPTKOANCCNFV-UHFFFAOYSA-N hexahydrate;hydrochloride Chemical compound O.O.O.O.O.O.Cl VOAPTKOANCCNFV-UHFFFAOYSA-N 0.000 description 1
• VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 230000002608 insulinlike Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 208000022013 kidney Wilms tumor Diseases 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
• 229960004942 lenalidomide Drugs 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 210000002418 meninge Anatomy 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229940071648 metered dose inhaler Drugs 0.000 description 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 1
• PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 1
• 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
• 229960005127 montelukast Drugs 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
• 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• RQFLGKYCYMMRMC-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O RQFLGKYCYMMRMC-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000005416 organic matter Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 208000008798 osteoma Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 201000007426 ovarian cystadenocarcinoma Diseases 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• 238000007243 oxidative cyclization reaction Methods 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• KECVZRCGVWMZOV-UHFFFAOYSA-N phenyl 1-methylcyclopropane-1-carboxylate Chemical compound CC1(CC1)C(=O)OC1=CC=CC=C1 KECVZRCGVWMZOV-UHFFFAOYSA-N 0.000 description 1
• DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 150000003906 phosphoinositides Chemical class 0.000 description 1
• 208000017983 photosensitivity disease Diseases 0.000 description 1
• RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
• 229960004633 pirenzepine Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 108010026735 platelet protein P47 Proteins 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 239000011698 potassium fluoride Substances 0.000 description 1
• 235000003270 potassium fluoride Nutrition 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
• 229940074439 potassium sodium tartrate Drugs 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 150000004672 propanoic acids Chemical class 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229940127293 prostanoid Drugs 0.000 description 1
• 150000003814 prostanoids Chemical class 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 210000005267 prostate cell Anatomy 0.000 description 1
• 229940076372 protein antagonist Drugs 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• SBMSLRMNBSMKQC-UHFFFAOYSA-N pyrrolidin-1-amine Chemical class NN1CCCC1 SBMSLRMNBSMKQC-UHFFFAOYSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 201000004335 respiratory allergy Diseases 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 150000003873 salicylate salts Chemical class 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 229910000077 silane Inorganic materials 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 208000014680 small intestine neoplasm Diseases 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
• 239000001593 sorbitan monooleate Substances 0.000 description 1
• 235000011069 sorbitan monooleate Nutrition 0.000 description 1
• 229940035049 sorbitan monooleate Drugs 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 229910052682 stishovite Inorganic materials 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 125000003107 substituted aryl group Chemical group 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 229940127230 sympathomimetic drug Drugs 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• YJBKVPRVZAQTPY-UHFFFAOYSA-J tetrachlorostannane;dihydrate Chemical compound O.O.Cl[Sn](Cl)(Cl)Cl YJBKVPRVZAQTPY-UHFFFAOYSA-J 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 229940062627 tribasic potassium phosphate Drugs 0.000 description 1
• 229910052905 tridymite Inorganic materials 0.000 description 1
• HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
• ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
• 229960002004 valdecoxib Drugs 0.000 description 1
• IAHBIMWHYUOIOH-UHFFFAOYSA-N vanadium hydrochloride Chemical compound Cl.[V] IAHBIMWHYUOIOH-UHFFFAOYSA-N 0.000 description 1
• 239000005526 vasoconstrictor agent Substances 0.000 description 1
• 210000003905 vulva Anatomy 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• 229960001095 xylometazoline hydrochloride Drugs 0.000 description 1